Vol. 1 No. 1 (2025): August, 2025

The inaugural issue of the Journal of Diabesity focuses on clinically relevant and real-world research at the intersection of obesity and diabetes. This issue features original survey-based investigations evaluating patient-reported outcomes related to commonly prescribed metabolic and gastrointestinal therapies, including empagliflozin discontinuation symptoms, real-world experiences with linaclotide, weight changes associated with rimegepant (Nurtec ODT), and comparative patient perspectives on glipizide and empagliflozin for type 2 diabetes management.

In addition, this issue presents a case report describing severe gastrointestinal intolerance and hepatic granulomas associated with semaglutide therapy, highlighting the importance of post-marketing pharmacovigilance in the era of expanding GLP-1 receptor agonist use.

Collectively, the articles emphasize real-world evidence, medication safety, patient adherence, and emerging adverse effects, establishing the journal’s commitment to advancing patient-centered metabolic research.